SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneer of AAV immuno-gene therapy for cancer, today revealed its lead asset, SRN-101, for the treatment of high-grade gliomas.
The actual amount distributed on the Payment Date listed above may differ from the estimated amount. Upon the completion of the reorganization, the assets of DFND will be transferred to, and the ...
Anaheim, CA (September 28, 2015) – Samsung Techwin America continues to develop solutions that deliver maximum performance and value with the release of its new NVRs at ASIS 2015 (booth # 1729).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results